|Treatments:||Chemotherapy||Hospital:||Istituto Nazionale Tumori|
This phase II study involved patients with stage IC to IV ovarian cancer not previously treated with chemotherapy who were separated into two different treatment groups. Groups A and B consisted of 410 patients each, and both groups had a median age of 57 years.
Patients in groups A were treated with the chemotherapy agents carboplatin and pegylated liposomal doxorubicin. Patients in group B were treated with the chemotherapy agents carboplatin and paclitaxel.
Treatment-related deaths due to bleeding and blood clotting were reported for group A. Also, grade 1-3 nausea, vomiting, and constipation were reported for this group, and 60% of patients reported grade 2 hair loss.
For group B, treatment-related deaths due to septic shock, sudden death, and fever were reported. Grade 1-3 nausea and stomatitis (inflammation of the stomach lining) was also reported for this group.
The median overall survival rates for groups A and B were 61.1 and 53.2 months, respectively. The median progression-free survival rates for groups A and B were 19.0 and 16.8 months, respectively.
This study was partially supported by Schering-Plough Pharmaceuticals.
Correspondence: Dr. Sandro Pignata; email: email@example.com